Avtor/Urednik		Regan, MM; Price, KN; Giobbie-Hurder, A; Thuerliman, B; Gelber, RD; Čufer, T; Pajk, B; Červek, J
Naslov		Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
Tip		članek
Vir		Breast cancer research
Vol. in št.		Letnik 26, št. 13
Leto izdaje		2011
Obseg		str. 1-13
Jezik		eng
Abstrakt		The Breast International Group (BIG) 1-98 study is a four-arm trial comparing 5 years of monotherapy with tamoxifen or with letrozole or with sequences of 2 years of one followed by 3 years of the other for postmenopausal women with endocrine-responsive early invasive breast cancer. From 1998 to 2003, BIG -98 enrolled 8,010 women. The enhanced design f the trial enabled two complementary analyses of efficacy and safety. Collection of tumor specimens further enabled treatment comparisons based on tumor biology. Reports of BIG 1-98 should be interpreted in relation to each individual patient as she weighs the costs and benefits of available treatments. Clinicaltrials.gov ID: NCT00004205.
Deskriptorji		BREAST NEOPLASMS TAMOXIFEN CHEMOTHERAPY, ADJUVANT RECEPTORS, ESTROGEN POSTMENOPAUSE SURVIVAL ANALYSIS PROPORTIONAL HAZARDS MODELS DOUBLE-BLIND METHOD CLINICAL TRIALS, PHASE III